TRKA increase during epithelial ovarian cancer progression, promoting cell proliferation and angiogenesis, by increasing several oncogenic proteins. Many reports have showed that microRNA-145 (miR-145) is down-regulated in EOC, promoting the increase of oncoproteins. Our aims of were to evaluate whether NGF changes the miR-145 levels in EOC cells and the role of this miR in vitro and in vivo experiments.

Methodology The human tissues and blood samples were obtained with informed consent and approved by Ethic Committee of our Institution. MicroRNA-145 levels were measured by qPCR in EOC samples, EOC cells lines (A2780 and SKOV3) and in serum samples. NGF action on miR-145 levels in EOC cell lines were evaluated using an inhibitor of TRKA (high affinity receptor of NGF). The over-expression of miR-145 in EOC cells were done by lipofectamine 2000 and by pGPGenti-CMV-GFP vector. As control we also used the empty vector. After the transfection assay it was evaluated the migration and invasion of A2780 and SKOV3 cells. After stable miR over-expression assays, the GFP-expressing cells were sorted using GFP mark and the in vivo assays were done. Animal studies were conducted in accordance with appropriate guidelines of Ethical Committee of the Institution. Two groups of Immune-compromised NOD/SCID mice were injected with 8 x10⁶ cells (intraperitoneal and subcutaneous) of A2780 or SKOV3 cells.

Results NGF decreased the miR-145 levels in A2780 and SKOV3 cell lines. Also, when an inhibitor of TRKA receptor was used, levels of this miR increased. Beside, miR-145 levels decreased with the EOC progression in both tissues and plasma samples. MicroRNA-145 over-expression in EOC cells decreased cell proliferation and invasion. Also, the stable over-expression of miR-145 in EOC cells lines decreased malignant ascites presence in the animals. On the other hand, a delay in the tumour formation was observed in EOC cells which over-express miR 145 in subcutaneous lateral flank compared with the mice injected with control EOC cells.

Conclusion These results suggest that overexpression/delivery of miR-145 could be a future adjuvant therapy in epithelial ovarian cancer

Disclosures The authors declare that there is no conflict of interest. This work was funded by Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) N° 1160139 to CR

94

RISK FACTORS FOR LYMPH NODE METASTASIS OF OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER IN HEREDITARY BREAST AND OVARIAN CANCER SYNDROME

¹Takashi Mitamura, ²Masayuki Sekine, ³Masami Arai, ⁴Shiro Yokoyama, ⁵Hiroko Yamashita, ⁶Hidemichi Watari, ⁷Ichiro Yabe, ⁸Hiroyuki Nomura, ⁹Takayuki Enomoto, ¹⁰Seigo Nakamura. ¹Hokkaido University Hospital; ²Niigata University Graduate School of Medical and Dental Science; ³Juntendo University, Graduate School of Medicine; ⁴Showa University School of Medicine; ⁵Hokkaido University Hospital; ⁶Fujita Health University

10.1136/ijgc-2020-ESGO.99

Introduction/Background To establish an individualized surgical strategy for ovarian cancer in patients with the germline BRCA1 and BRCA2 pathogenic variants (BRCA1+ and BRCA2+), we investigated the clinicopathological

characteristics that are involved in the increased risk of lymph node metastasis (LNM).

Methodology We retrospectively reviewed the data of 509 Japanese women who underwent BRCA1 and BRCA2 genetic testing and were registered in the database of the Japanese HBOC Consortium.

Results BRCA1+ and BRCA2+ were found in 232 (45.6%) of patients in our database, while other patients had no pathogenic variant (BRCA-). The prevalence of LNM was not markedly different between BRCA- (19.5%), BRCA1+ (18.4%) and BRCA2+ (26.2%). Multivariate analysis revealed an absence of a family history of ovarian cancer as an independent predictor for an increased risk of LNM in BRCA1+, and the prevalence of LNM was 11.7% and 42.0% in the groups with and without a family history of ovarian cancer, respectively. This subgroup without a family history of ovarian cancer did not show any correlation with a particular variant of BRCA1.

Conclusion This study suggested that the existence of a subgroup in which the absence of a family history of ovarian cancer was an independent predictor for an increased risk of lymph node metastasis and certain genetic factors related to the penetrance of hereditary breast and ovarian cancer syndrome might alter the frequency of LNM in BRCA1+ ovarian cancer. We will need to investigate whether or not the same surgical strategy for lymphadenectomy as BRCA- is suitable for this BRCA1+ subgroup.

Disclosures There are no conflict of interest disclosures from any authors.

108

CONDITIONAL RELATIVE SURVIVAL OF OVARIAN CANCER : A KOREAN NATIONAL CANCER REGISTRY STUDY

¹Jaeman Bae, ²Dong Wook Shin, ³Kyu-Won Jung. ¹Hanyang University College of Medicine; Department of Gynecologic Oncology; ²Department of Family Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; ³The Korea Central Cancer Registry, National Cancer Center; 323 Ilsan-Ro, Ilsandong-Gu, Goyang-Si, Gyeonggi-Do

10.1136/ijgc-2020-ESGO.100

Introduction/Background Conditional relative survival (CRS) considers changes in prognosis over time and thus, may offer more useful estimates for survivors and clinicians. We aimed to investigate the CRS among patients with ovarian cancer with comprehensive stratification by various factors that influence survival probabilities.

Methodology This nationwide retrospective cohort study used data from the Korean Central Cancer Registry. We included 78,606 patients diagnosed with cervical cancer as their first cancer between January 1, 1997 and December 31, 2016. CRS and the conditional probabilities of death for the following 1 year were calculated stratified by age at diagnosis, histology, stage at diagnosis, year of diagnosis, and social deprivation index.

Results The 5-year relative survival rate at the time of diagnosis was 61.1% for all cases. The probability of surviving an additional 5 years conditioned on having already survived 1, 2, 3, 4, and 5 years after diagnosis was 65.0%, 69.5%, 74.6%, 79.3%, and 83.9%. Patients with poorer initial survival estimates (older, advanced stage) generally showed the